Rapid identi cation of Candida species facilitates pathogen-directed therapy with either uconazole or an echinocandin.
Introduction
Candidaemia is a signifi cant cause of sepsis, with C. albicans and C. glabrata accounting for the majority of bloodstream infections caused by yeasts. 1 There has been a shift in the epidemiology of candidaemia in Scotland with a rise in the proportion of C. glabrata over the last decade.
1,2 An emergent multi-resistant species, C. auris, recently caused a major outbreak in England, which highlights the importance of invasive yeast infections. 3 Risk factors for candidaemia include broad-spectrum antibiotics, total parenteral nutrition, use of chemotherapeutic agents, admission to intensive care units, and the presence of central venous catheters. 4 Fluconazole and echinocandins (anidulafungin, caspofungin, and micafungin) are widely used for treating candidaemia. Echinocandins are very expensive compared to fl uconazole but are also more reliable. However, widespread use of echinocandins may lead to emergence of resistance. 5 The antifungal susceptibility of Candida is generally predictable if the infecting species is known (Table 1) . 6 However, conventional diagnostic methods to identify the infecting species may take 72 h. 7 In order to optimise the use of echinocandins, a clinical risk-factor based approach has been suggested by the Infectious Diseases Society of America (IDSA). 6 This approach relies on certain risk factors for C. glabrata bloodstream infection including diabetes, malignancy, history of recent azole use, and advanced age. In patients with these risk factors, echinocandin therapy is indicated with a subsequent switch to fl uconazole if the identifi ed species is likely to be susceptible. Echinocandins are also favoured in patients who are haemodynamically unstable or are neutropaenic as these patients are more likely to suffer adverse consequences if their initial treatment is suboptimal. Fluconazole is an alternative in patients without risk factors for C. glabrata. Guidelines from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) favour the use of echinocandin over fl uconazole irrespective of risk factors. 8 Rapid identifi cation of microbial species provides opportunities for antimicrobial stewardship programmes by reducing turnaround time, thereby favouring targeted rather than empirical prescribing. In relation to candidaemia, identifi cation of species on the day of positive blood culture eliminates the need for risk stratifi cation by targeting treatment directed towards the infecting species at the time of commencement of therapy. At University Hospital Crosshouse, we introduced matrix-assisted laser desorption ionisation-time of fl ight mass spectrometry (MALDI-TOF-MS) (Bruker Daltoniks, Germany) in January 2014 as part of laboratory modernisation following approval from the laboratory directorate. This enabled us to offer rapid identifi cation of bacteria and yeasts from positive blood cultures, replacing the biochemical identification systems which are based on sugar fermentation reactions. In this report we describe our fi ndings in relation to the usefulness of MALDI-TOF-MS technology in streamlining antifungal therapy.
Methods

Patients and setting
The microbiology laboratory based at University Hospital Crosshouse, Kilmarnock, provides diagnostic services to a population of 368,000 covered by NHS Ayrshire & Arran. Adult patients with candidaemia from January 2014 to September 2017 were identifi ed with the help of Laboratory Information Management Systems. Patient demographics and information on risk factors including past medical history of diabetes or malignancy, use of azole antifungal agents in the 30 days prior to candidaemia, and presence of haemodynamic instability (systolic blood pressure ≤ 90 mmHg with requirement for vasoconstrictor agents), 9, 10 were obtained from the electronic patient management system, Laboratory Information Management Systems, and case records.
Appropriateness of antifungal agents and costs
Fluconazole and micafungin are available on our hospital formulary for the treatment of candidaemia. Microbiologists offer advice on treatment based on patient factors and laboratory fi ndings in consultation with the clinical teams and the patient. Details of treatment received by the patients were obtained from the electronic medicines management system. Defi ned daily dosages (DDD) for micafungin (standard dose 100 mg daily) and intravenous fl uconazole (standard dose 800 mg loading followed by 400 mg daily) were 100 mg and 200 mg and the acquisition cost per DDD was £341 and £29.28, respectively. 11 Although fl uconazole can also be administered orally for the treatment of candidaemia, we assumed that all dosages were administered by intravenous route for the purpose of analysis. To ascertain cost savings, we audited our fi ndings against the treatment recommendation made by the IDSA guideline for each episode of candidaemia. 6 Cost saving was the difference between the cost of the DDDs that might have been consumed had therapy been based on the IDSA guideline and the cost of DDD actually consumed where results of rapid species identifi cation were available at the time of prescribing. We assumed that for fl uconazole-susceptible isolates, switching of therapy from micafungin to fl uconazole would have normally occurred after three days. 11 For the purpose of data analysis, echinocandins were considered as appropriate/recommended treatment in patients with C. glabrata and C. krusei while fl uconazole was appropriate treatment for all other species isolated during the study period (Table 1) .
Microbiological investigations
Blood cultures were processed using the BacT/Alert 3D system (bioMerieux, Marcy-l'Etoile, France) with 5 days incubation period. Positive blood culture broths were inoculated on to Sabouraud's agar as part of conventional diagnostics. After 24-48 h incubation, subsequent growth from culture plates was identifi ed by MALDI-TOF-MS, which is a new laser-based diagnostic technique. In addition, positive blood culture bottles were subjected to same day rapid identifi cation by a special technique, Sepsityper MALDI-TOF-MS, which is directly applied to fl uid specimens such as blood culture broths. 12 Rapid identifi cation by Sepsityper MALDI-TOF-MS was routinely available only on weekdays (Monday-Friday, 9am to 5pm). Antifungal susceptibility testing was carried out using the YeastOne colourimetric microdilution test (ThermoScientifi c, Trek Diagnostic Systems, West Sussex, UK). Results were communicated to the clinical teams on the day they were generated.
Statistical analysis
The chi-square (or Fisher exact test where a cell value was 0) was used to compare the categorical variables and p values of ≤ 0.05 were considered to indicate statistical significance. 
Results
Seventy-four patients (age range 26-93) had candidaemia during the study period yielding 75 Candida isolates (one patient had mixed infection). Most patients had at least one clinical risk factor for infection with C. glabrata including age ≥ 65 years (n = 40), diabetes (n = 30), malignancy (n = 30), and prior azole use (n = 3), with some having multiple risk factors. However, C. glabrata was recovered in only a minority of patients with risk factors. Four patients were haemodynamically unstable at the time of candidaemia and only one patient was neutropaenic. Table 2 gives the details of species that were isolated. Five isolates were resistant to fl uconazole (four isolates of C. krusei and one C. glabrata), 16 were intermediate (C. glabrata), while the remaining were susceptible. Thirty-four out of 74 blood cultures fl agged positive outside routine working hours and were subjected to conventional diagnostic methods only. The remaining 40 positive blood cultures were subjected to Sepsityper MALDI-TOF-MS. We were able to identify the species of Candida in 25 (62.5%) of these 40 samples. Thus, in 49 patients we did not have the benefi t of rapid species identifi cation while in 25 patients rapid identifi cation was successful. Comparative data of the two patient groups are shown in Table 2 .
Species identifi cation based on conventional techniques
Forty-fi ve of 49 patients whose Candida isolates were only identifi ed following growth on solid media were treated with an antifungal agent: 20 (44.4%) received echinocandin therapy and 25 (55.5%) received fl uconazole. Four were not treated: two had their treatment withdrawn by the time bloodstream infection was detected and in the remaining two, yeasts were dismissed as contaminants on clinical grounds. Although an overwhelming number (44/49) of patients had risk factors for C. glabrata, only 12 had C. glabrata recovered from their bloodstream. On matching the prescribed treatment with the isolates, 28 (62.2%) of 45 patients were found to have been treated with an antifungal agent appropriate for the species (Table 2) . 
Rapid species identifi cation
Of the 25 patients with candidaemia who had the species identifi ed on the same day, 22 (88%) received antifungal therapy (two had died by the time candidaemia was detected while in one case, the yeast was dismissed as a contaminant). If the treatment had been based on the clinical practice guidelines of the IDSA, 17 patients would have received micafungin and the remaining 5 would have received fl uconazole. However, only 3 (13.6%) of 22 patients received micafungin and the remaining 19 (86.3%) received fl uconazole, which may have been infl uenced by the rapid identifi cation of the infecting species. Rapid species identifi cation thus had a demonstrable effect on the choice of therapy which helped reduce the cost of treatment by preferential use of fl uconazole in patients infected with species that are usually susceptible to it. Rapid identifi cation also led to targeted treatment: preferential use of fl uconazole in patients with C. parapsilosis and micafungin in patients with C. glabrata or C. krusei. Prescribing was significantly more appropriate in the rapid identification group with 20 (90.9%) of 22 patients receiving appropriate therapy compared to only 62.2% for patients in whom rapid identifi cation was not available (p = 0.01) ( Table 2) . Data from the groups of patients are summarised in Table 3 .
There were no discrepancies between the Sepsityper MALDI-TOF-MS aided direct identifi cation from broths and the subsequent MALDI-TOF-MS based identifi cation from culture plates.
Cost savings
We estimated cost savings of £13,299 related to avoidance of 39 DDDs of micafungin in 13 patients each receiving 1 DDD of micafungin per day for 3 days (Table 3 : Groups 2 and 3). We incurred an expenditure of £3045.12 on the 104 DDDs of fl uconazole for 13 patients each receiving 8 DDDs of fl uconazole over the fi rst 3 days (Table 3 : Groups 2 and 3) giving a net cost saving of £10,253.88 and average cost saving of £466.08 per successful species identifi cation in patients who received therapy.
The overall 30-day crude mortality was 24.3% (21.7% for patients commenced on echinocandin, 20.4% for patients commenced on fl uconazole).
Discussion
Individual species of Candida have predictable antifungal susceptibility patterns, although exceptions are encountered. Species identifi cation is most relevant for C. glabrata and C. krusei as fl uconazole is relatively or absolutely contraindicated in their treatment. There are also concerns about the activity of echinocandins against C. parapsilosis. Consequently, the IDSA guidelines recommend echinocandins in situations where the risk of C. glabrata is high. 6 However, experts agree that treatment of candidaemia needs to be individualised. 13 In this regard, rapid species identification is beneficial because early appropriate treatment of candidaemia 14 In addition, the pharmacokinetic and pharmacodynamic data also infl uence the choice of therapy, e.g. fl uconazole may be the preferred agent for infections in the urinary tract or the central nervous system where echinocandins penetrate poorly. Azoles, on the other hand, have signifi cant drug interactions compared to echinocandins. Source control, central venous catheter removal, funduscopic examination, echocardiography, and daily blood cultures until a documented clearance of bloodstream infection are also recommended in all cases of candidaemia. 8 Our data reveal a signifi cantly greater degree of appropriate usage of antifungal agents when species identifi cation was available.
We also show that risk factors are poorly discriminatory as we recovered C. glabrata from only a minority of patients. The evidence base for risk-stratifi cation is weak. 15 Risk assessment for C. glabrata is rendered obsolete with the availability of rapid species identifi cation by Sepsityper MALDI-TOF-MS, which merits consideration in future updates of guidelines. The use of Sepsityper MALDI-TOF-MS may have led to optimisation of antifungal therapy, which is supported by antimicrobial stewardship programmes. 16 We made signifi cant savings which might be more than what we estimated because the proportion of patients who get step-down therapy in clinical practice is only 20-40%. 17 Also, our projected savings would be more if we audited against the ESCMID guidelines which advise commencing therapy with echinocandins for all patients prior to the knowledge of infecting species. 8 In our analysis, we assumed that fl uconazole was given by the intravenous route which further moderated the cost savings as oral fl uconazole is cheaper compared to the intravenous formulation. On the other hand, our data reveal that fl uconazole was still the favoured therapy for patients who did not have the benefi t of rapid identifi cation despite the fact that an overwhelming majority of them had risk factors for C. glabrata (Table 2) , perhaps because the association of risk factors with C. glabrata is not convincing. 15 In the rapid identifi cation group, we would not necessarily have used micafungin solely on account of risk factors. The real benefi t of rapid testing is facilitation of pathogen-directed therapy.
Our fi ndings support the Scottish strategy on antimicrobial stewardship. The Scottish Antimicrobial Prescribing Group supports optimisation of antimicrobial prescribing through quality improvement initiatives. 18 An important barrier to antimicrobial optimisation is the delay in obtaining results.
Previous studies based on cost-minimisation models have predicted a cost saving of $1800 per patient with the use of rapid diagnostic tools. 19 McMullan et al. demonstrated a statistically non-significant reduction in empirical antifungal usage in an intensive care unit setting following introduction of a serum polymerase chain reaction assay which discriminates between the fl uconazole-susceptible and -resistant species. 20 We focused on defi nitive therapy in proven cases of candidaemia which enabled us to measure the appropriateness of treatment. Rapid testing has usefulness in invasive bacterial infections also, e.g. differentiating, on the day of the positive blood culture, Staphylococcus aureus from coagulase-negative staphylococci, the latter usually being contaminants.
There are drawbacks in our study. The dataset has limited numbers. We have reported a success rate of 62.5% with Sepsityper MALDI-TOF-MS for direct identifi cation of Candida species from blood culture broths, which is within the range of 56-62.5% reported in the literature but it still needs improvement. 21, 22 A greater success rate has also been reported. 23 Our basis for classifying the appropriateness of the antifungal agents was the predicted susceptibility pattern based on species identifi cation. In practice, echinocandins are suitable treatment for many Candida species in addition to C. glabrata and C. krusei. Anidulafungin therapy was found to be superior compared to fl uconazole in a randomised controlled trial on candidaemia in which a majority of patients had infection with C. albicans. 24 However, the fact that the IDSA recommends echinocandins for patients who are at risk of C. glabrata and fl uconazole as an alternative in patients without risk factors implies that the expected susceptibility profi le based on species identifi cation should be considered when choosing antifungal treatment. Changes in epidemiology of Candida, local susceptibility profi le, local guidelines on the choice of antifungal agents and the decline in the acquisition cost of echinocandins may affect the reproducibility of our results. Occasionally, the susceptibility pattern might not be on predictable lines. We have previously reported a case of echinocandin-resistant C. albicans. 25 On the other hand, pathogen-directed targeted treatment might still be benefi cial by streamlining antifungal therapy with reduction in the risk of development of resistance. Our data suggest that Sepsityper MALDI-TOF-MS supports antifungal stewardship by optimising therapy in patients with candidaemia with a possible relationship between rapid species identifi cation and antifungal usage.
